December 2022 - Combat Group

Short-term use of HIVEC in intermediate risk bladder-cancer patients is non-inferior to classical treatments and longer-term use shows great promise in Spanish trial

by Combat Cancer | Dec 1, 2022 | News

Press release, 1 December 2022 Combat Medical is pleased to announce the results of the HIVEC I phase 3 randomised controlled trial, published in European Urology Oncology on 23 November 2022. As with this year’s HIVEC II publication, this short-term regimen shows...

Short-term use of HIVEC in intermediate risk bladder-cancer patients is non-inferior to classical treatments and longer-term use shows great promise in Spanish trial

Recent Posts

Recent Comments

Archives

Categories

Meta